Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease

被引：203

作者：

Rosenson, Robert S. ^{[1
]}

Davidson, Michael H. ^{[2
]}

Hirsh, Benjamin J. ^{[3
]}

Kathiresan, Sekar ^{[4
]}

Gaudet, Daniel ^{[5
,6
]}

机构：

[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[2] Univ Chicago, Pritzker Sch Med, Div Cardiol, Chicago, IL 60637 USA

[3] Mt Sinai Hosp, New York, NY 10029 USA

[4] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA

[5] Univ Montreal, Dept Med, ECOGENE 21, Chicoutimi, PQ, Canada

[6] Univ Montreal, Dept Med, Lipid Clin, Chicoutimi, PQ, Canada

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2014年 / 64卷 / 23期

关键词：

atherosclerosis; cardiovascular disease; genetics; triglyceride; triglyceride-rich lipoproteins; LOW-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; APOLIPOPROTEIN C-III; ALIPOGENE TIPARVOVEC AAV1-LPLS447X; TISSUE-SPECIFIC EXPRESSION; CYTOSOLIC LIPID DROPLETS; GENOME-WIDE ASSOCIATION; EXTENDED-RELEASE NIACIN; NONFASTING TRIGLYCERIDES; SEVERE HYPERTRIGLYCERIDEMIA;

D O I：

10.1016/j.jacc.2014.09.042

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Triglycerides represent 1 component of a heterogeneous pool of triglyceride-rich lipoproteins (TGRLs). The reliance on triglycerides or TGRLs as cardiovascular disease (CVD) risk biomarkers prompted investigations into therapies that lower plasma triglycerides as a means to reduce CVD events. Genetic studies identified TGRL components and pathways involved in their synthesis and metabolism. We advocate that only a subset of genetic mechanisms regulating TGRLs contribute to the risk of CVD events. This " omic" approach recently resulted in new targets for reducing CVD events. (C) 2014 by the American College of Cardiology Foundation.

引用

页码：2525 / 2540

页数：16

共 50 条

[41] Remnant lipoproteins and atherosclerotic cardiovascular disease
Tada, Hayato
Nohara, Atsushi
Inazu, Akihiro
Mabuchi, Hiroshi
Kawashiri, Masa-aki
CLINICA CHIMICA ACTA, 2019, 490 : 1 - 5
[42] Do Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?
Wadstroem, Benjamin N.
Wulff, Anders B.
Pedersen, Kasper M.
Nordestgaard, Borge G.
CURRENT ATHEROSCLEROSIS REPORTS, 2023, 25 (11) : 795 - 803
[43] GPIHBP1 and the processing of triglyceride-rich lipoproteins
Beigneux, Anne P.
CLINICAL LIPIDOLOGY, 2010, 5 (04) : 575 - 582
[44] Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins
Visser, Jolien
van Zwol, Willemien
Kuivenhoven, Jan Albert
CURRENT ATHEROSCLEROSIS REPORTS, 2022, 24 (01) : 1 - 12
[45] Triglycerides and triglyceride-rich lipoproteins in the development and progression of atherosclerosis
Generoso, Giuliano
Janovsky, Carolina C. P. S.
Bittencourt, Marcio S.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2019, 26 (02) : 109 - 116
[46] Lipidomics of triglyceride-rich lipoproteins derived from hyperlipidemic patients on inflammation
Moreno-Vedia, Juan
Llop, Didac
Rodriguez-Calvo, Ricardo
Plana, Nuria
Amigo, Nuria
Rosales, Roser
Esteban, Yaiza
Masana, Lluis
Ibarretxe, Daiana
Girona, Josefa
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2024, 54 (03)
[47] Associations of intra-pancreatic fat deposition with triglyceride-rich lipoproteins and lipoprotein lipase
Liu, Yutong
Skudder-Hill, Loren
Kimita, Wandia
Shamaitijiang, Xiatiguli
Sequeira-Bisson, Ivana R.
Petrov, Maxim S.
DIABETES OBESITY & METABOLISM, 2025, : 3233 - 3241
[48] The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
Boren, Jan
Packard, Chris J.
Taskinen, Marja-Riitta
FRONTIERS IN ENDOCRINOLOGY, 2020, 11
[49] Are triglyceride-rich lipoproteins associated with aortic valve sclerosis? A preliminary report
Gerber, Y
Goldbourt, U
Feinberg, MS
Segev, S
Harats, D
ATHEROSCLEROSIS, 2003, 170 (02) : 301 - 305
[50] Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans
Doi, Takahito
Langsted, Anne
Nordestgaard, Borge G.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2023, 30 (11) : 1525 - 1546

← 1 2 3 4 5 →